@Article{oncologie.2022.022116, AUTHOR = {Yang Chen, Huan Wu, Annan Jiao, Jiabing Tong, Jie Zhu, Mei Zhang, Zegeng Li, Ping Li}, TITLE = {Chinese Herbal Prescription QYSL Prevents Progression of Lung Cancer by Targeting Tumor Microenvironment}, JOURNAL = {Oncologie}, VOLUME = {24}, YEAR = {2022}, NUMBER = {2}, PAGES = {295--307}, URL = {http://www.techscience.com/oncologie/v24n2/48743}, ISSN = {1765-2839}, ABSTRACT = {Objectives: Lung cancer is a common and malignant tumor in adults and ranks first in the incidence and mortality of the top five malignant tumors in China. Our previous studies have shown that QYSL prescription can balance lung cancer mice Th1/Th2 and inhibit tumor cell immune escape. Here, we examined the effects of QYSL on lung cancer associated macrophage and the potential associated mechanism. Methods: C57BL/6 mice were injected with Lewis lung cancer cells and treated with QYSL. FACS, RT-PCR, and western blot were used to examined the effect of QYSL on tumor immune microenvironment. Results: We found QYSL inhibited tumor growth in mice with lung cancer. Further study indicated that QYSL inhibited growth of lung tumor by promoting T cell activation and promoting macrophage polarization to M1 type. We found QYSL could markedly inhibit M2 macrophage related protein expression and promote M1 macrophage related protein expression. Additionally, STAT6 and MTOR expression were reduced in QYSL group. Conclusions: Overall, this study indicated that QYSL potently inhibited the growth of lung cancer by promoting T cell activation and M2 macrophage polarization to M1, which was found to be associated with the STAT6 and MTOR signaling pathway.}, DOI = {10.32604/oncologie.2022.022116} }